Evidence map›Paper›PMID 36515796›Full record

ArticleInternational journal of hematology2023

Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan.

Yoshimitsu Shimomura, Tetsuhisa Kitamura, Masashi Nishikubo, Tomotaka Sobue, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Ayumu Ito, Jun Ishikawa, Takahide Ara and 12 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 18 institutions in 1 country.

Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, Chuo-Ku, Kobe, 650-0047, Japan. shimomura_0119@yahoo.co.jp.ORCID http://orcid.org/0000-0003-1018-9508
Tetsuhisa KitamuraDepartment of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Masashi NishikuboDepartment of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Minamimati 2-1-1, Minatojima, Chuo-Ku, Kobe, 650-0047, Japan.
Tomotaka SobueDepartment of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, Kanagawa, Japan.
Ayumu ItoDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan.
Takahide AraDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Shuichi OtaDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Makoto OnizukaDepartment of Hematology, Tokai University School of Medicine, Kanagawa, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan.
Yumiko MaruyamaDepartment of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.
Kazuhiro IkegameDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Tatsuo IchinoheDepartment of Hematology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Shinichiro OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Takanori TeshimaDepartment of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Kobe City Medical Center General Hospital · JPThe University of Osaka · JPAichi Medical University · JPAnjo Kosei Hospital · JPHiroshima University · JPHokkaido University · JPHokkaido University Hospital · JPHyogo University · JPJapanese Red Cross Nagoya Daiichi Hospital · JPJichi Medical University · JPKanagawa Prefectural Hospital Organization · JPKeio University · JPOsaka International Cancer Institute · JPSapporo Hokuyu Hospital · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPToranomon Hospital · JPUniversity of Tsukuba Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic affected healthcare quality and access worldwide and may also have negatively affected the frequency and outcomes of allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated the effect of the pandemic on allogeneic HSCT in Japan. Our subjects were patients who received allogeneic HSCT during January 2018-December 2020 in Japan. We assessed differences in yearly number of allogeneic HSCTs and 1-year outcomes in 2020 versus both 2019 and 2018. The total number of patients who received allogeneic HSCT increased from 3621 patients in 2018 and 3708 patients in 2019 to 3865 patients in 2020. Some following changes in allogeneic HSCT methods were observed: patients were older, fewer patients received bone marrow transplantation, fewer patients received transplants from unrelated donors, fewer patients received transplants from matched donors, more patients received reduced-intensity conditioning, and fewer patients received anti-thymocyte globulin in 2020 compared with previous years. HSCT outcomes were not affected, as 1-year overall survival was not significantly different (65.8% in 2020, vs. 66.5% in 2019 and 66.4% in 2018). Our results suggest that we can maintain transplant care during the pandemic by controlling the spread of COVID-19 and modifying HSCT methods.

Indexed as

COVID-19Graft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansJapanPandemicsTransplantation ConditioningUnrelated DonorsAllogeneic hematopoietic stem cell transplantationCoronavirus disease 2019PandemicSocial restrictionTransplant activity and outcome

Identifiers

PMID36515796
PMCPMC9749640
OpenAlexW4311462722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.